BIOMAT Database Logo BIOMAT Database Logo

Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia. 1995

C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Department of Internal Medicine and Geriatrics, University of Palermo, Italy.

Hypercholesterolemia has been recognised as a primary risk factor for coronary heart disease. Reduction of plasma levels of total and LDL cholesterol has been shown to decrease coronary atherosclerosis. Plasmapheresis represents an useful non-pharmacological tool to treat severe hypercholesterolemias. We have evaluated the effectiveness of a system of plasmapheresis using a cascade filtration method in two young male subjects (aged 16 and 26 years) with homozygous familial hypercholesterolemia. Both showed severe coronary atherosclerosis as determined by angiography. Procedures were performed at intervals of 7 days in each case. We observed a mean reduction of plasma levels of total cholesterol of 59.5% (range 31.0-75.5%); LDL-cholesterol, 61.6% (range 32.6-77.1%); triglycerides, 48.1%; HDL-cholesterol, 31.1%; apo A-I, 30.8%; and apo B, 57.6%. We also noted a reduction of other parameters, such as fibrinogen (49.9%) and Lp(a) (59.9%). At the end of each procedure about 8 g of cholesterol was removed from the total body pool. A decrease of total proteins (26.9%) and albumin (19.6%) was also observed, but this was completely restored before the next apheresis (1 week). These data show the effectiveness of the removal of LDL in a cascade filtration system, which obtains results not very different from other more selective methods. The lack of selectivity is not much of a problem, since it also reduces other risk factors such as Lp(a) and fibrinogen.

UI MeSH Term Description Entries
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008297 Male Males
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D005374 Filtration A process of separating particulate matter from a fluid, such as air or a liquid, by passing the fluid carrier through a medium that will not pass the particulates. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Filtrations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis.
December 2012, Turkish journal of haematology : official journal of Turkish Society of Haematology,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Familial homozygous hypercholesterolemia: effective long-term treatment with cascade double filtration plasmapheresis.
January 2001, Blood purification,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Cascade filtration for familial hypercholesterolemia.
December 1991, The International journal of artificial organs,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis.
August 1986, Atherosclerosis,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Plasmapheresis in familial hypercholesterolemia.
January 1989, Arteriosclerosis (Dallas, Tex.),
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
[Comparative analysis of plasmapheresis and cascade plasma filtration in the management of patients with hereditary hypercholesterolemia].
January 1987, Terapevticheskii arkhiv,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Double-filtration plasmapheresis in heterozygous familial hypercholesterolemia: our experience over 25 treatments.
January 1988, Beitrage zur Infusionstherapie = Contributions to infusion therapy,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Familial Hypercholesterolemia: Cascade Screening in Children and Relatives of the Affected.
May 2018, Indian journal of pediatrics,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Low-density lipoprotein apheresis by membrane differential filtration (cascade filtration) via arteriovenous fistula performed in children with familial hypercholesterolemia.
February 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
C M Barbagallo, and M R Averna, and T DiMarco, and L Spano, and V Scafidi, and G Marino, and A R Camemi, and A Notarbartolo
Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients.
April 1996, Artificial organs,
Copied contents to your clipboard!